Source: International Congress 2017 – COPD management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Vogelmeier (Marburg, Germany). Low rate of exacerbations following initiation of LABA/LAMA fixed-dose combinations: An analysis of the DACCORD real life study. 1070

Member's Comments

No comment yet.

Related content which might interest you: LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment Source: Eur Respir Rev 2017; 26: 160043 Year: 2017 Asthma control and lung function after step down from high dose ICS/LABA combination therapy Source: Annual Congress 2011 - Asthma management and response Year: 2011 Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use? Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Pooled analysis of 24-h lung function following treatment with the LAMA/LABA glycopyrronium/formoterol fumarate fixed-dose combination, delivered by a novel MDI co-suspension technology (GFF MDI), in COPD patients (pts) Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Comparison of efficacy and safety of fixed-dose combination regimen versus separate drugs for treatment of tuberculosis Source: International Congress 2019 – Insights into paediatric bronchology Year: 2019 Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Effect of salmeterol/fluticasone propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality: INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations) study Source: Eur Respir J 2007; 30: Suppl. 51, 34s Year: 2007 LABA/LAMA combinations efficacy evaluation therapy of COPD patients with emphasized morning and night symptoms Source: International Congress 2018 – COPD management Year: 2018 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Factors influencing LAMA addition to COPD patients receiving ICS/LABA in clinical practice-RETRIEVE study. Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS) Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007 Total costs according to reliever use of formoterol turbuhaler in asthma: results from the RELIEF worldwide randomized effectiveness study, stratified by maintenance medication levels Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002